XML 32 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events
3 Months Ended
Mar. 31, 2015
Subsequent Events [Abstract]  
Subsequent Events
12.Subsequent Events

In April, 2015, the Company’s exclusive licensee, Lorem Vascular Pte. Ltd., was granted regulatory clearance for the Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China (the “CFDA”). The CFDA clearance triggered certain purchasing obligations for Lorem Vascular, for Cytori Celution Devices and Cytori Celution Consumable Sets. Pursuant to the agreement, Lorem Vascular has submitted their initial purchase order upon receiving CFDA clearance.

On May 5, 2015, we entered into a Securities Purchase Agreement with certain institutional investors pursuant to which the Company agreed to sell up to $25 million of units for a purchase price of $0.77 per unit, with each unit consisting of one share of the its common stock and one warrant to purchase one share of its common stock, in a registered direct offering. Each warrant will have an initial exercise price of $1.02 per share, will be exercisable six months after the date of issuance and expires five years from the date it becomes exercisable. The offering will have two separate closings, the first closing of $19.4 million took place on May 8, 2015 and the second close is subject to shareholder vote, which is anticipated to take place in August 2015.